GlassScriptPhysician profile
Rajneesh Nath
NPI 1912968728
$42,250.59
in general payments reported to CMS, 2019-2025
23 companies · $6,882 in 2025
The $6,882 reported for 2025 was more than what 85% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $180 · 2021: $125 · 2022: $253 · 2023: $4,789 · 2024: $15K · 2025: $6,882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Honoraria: $5,130 · Travel and Lodging: $3,480 · Food and Beverage: $1,473 · Education: $79.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,864.00 |
| Honoraria | $5,130.00 |
| Travel and Lodging | $3,480.01 |
| Food and Beverage | $1,473.46 |
| Education | $79.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adc Therapeutics America, INC. | $14,856.53 | 2023-2024 | |
| Astellas Pharma Global Development | $7,943.55 | 2019 | |
| Daiichi Sankyo INC. | $6,116.51 | 2019 | |
| Autolus INC | $5,391.04 | 2025 | |
| Adaptive Biotechnologies Corporation | $3,166.36 | 2020-2025 | Clonoseq |
| E.R. Squibb & Sons, L.L.C. | $1,983.81 | 2022-2024 | |
| Celgene Corporation | $1,182.86 | 2022-2024 | |
| Cti Biopharma Corp. | $294.99 | 2022-2023 | Vonjo |
| Merck Sharp & Dohme LLC | $232.13 | 2019 | |
| Incyte Corporation | $203.54 | 2021-2023 | |
| Abbvie INC. | $127.85 | 2019-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $119.50 | 2023 | Epkinly |
| Pfizer INC. | $115.94 | 2019 | |
| Novartis Pharmaceuticals Corporation | $103.05 | 2019 | |
| Sanofi-Aventis U.S. LLC | $100.00 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $95.00 | 2019 | |
| Karyopharm Therapeutics INC. | $90.87 | 2025 | Xpovio |
| Beigene USA, INC. | $86.30 | 2023 | Brukinsa |
| Janssen Biotech, INC. | $28.49 | 2019 | |
| Eisai INC. | $12.27 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajneesh Nath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.